Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ritobegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 7/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | GALR3 | O60755 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ritobegron SCHEMBL2950593 | 1.00 | ADRB3 (0.63) | ADRB3LMNASLC6A2SLC6A4OPRM1 | |
| Ritobegron SCHEMBL2949688 | 1.00 | ADRB3 (0.63) | ADRB3LMNASLC6A2SLC6A4OPRM1 | |
| Ritobegron SCHEMBL2950589 | 1.00 | ADRB3 (0.63) | ADRB3LMNASLC6A2SLC6A4OPRM1 | |
| Ritobegron SCHEMBL1404071 | 0.99 | ADRB3 (0.64) | ADRB3LMNASLC6A2SLC6A4OPRM1 | |
| Ritobegron SCHEMBL4186380 | 0.99 | ADRB3 (0.64) | ADRB3LMNASLC6A2SLC6A4OPRM1 | |
| Ritobegron SCHEMBL5916906 | 0.99 | ADRB3 (0.64) | ADRB3LMNASLC6A2SLC6A4OPRM1 | |
| Ritobegron SCHEMBL1404072 | 0.99 | ADRB3 (0.64) | ADRB3LMNASLC6A2SLC6A4OPRM1 | |
| Ritobegron SCHEMBL4108225 | 0.93 | ADRB3 (0.58) | ADRB3LMNASLC6A2SLC6A4OPRM1 | |
| SCHEMBL13653968 | 0.91 | ADRB3 (0.54) | ADRB3LMNASLC6A2SLC6A4OPRM1 | |
| SCHEMBL13653975 | 0.91 | ADRB3 (0.54) | ADRB3LMNASLC6A2SLC6A4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763654-B2 | Crystal polymorph of hydroxynorephedrin derivative hydrochloride | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | claimed |
| US-20100172988-A1 | SUSTAINED RELEASE PREPARATION AND METHOD FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-07-08 | — | — | US | claimed |
| US-20090069421-A1 | CRYSTAL POLYMORPH OF HYDROXYNOREPHEDRIN DERIVATIVE HYDROCHLORIDE | KISSEI PHARMACEUTICAL CO., LTD, (JP) | 2009-03-12 | — | — | US | claimed |
| US-7446128-B2 | Agent for treating interstitial cystitis | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-11-04 | — | — | US | claimed |
| EP-1974725-A1 | SUSTAINED RELEASE PREPARATION AND METHOD FOR PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2008-10-01 | — | — | EP | claimed |
| EP-1620085-B1 | USE OF PHENOXYACETIC ACID DERIVATIVES FOR TREATING HYPERACTIVE BLADDER | KISSEI PHARMACEUTICAL (JP) | 2008-07-23 | — | — | EP | claimed |
| EP-1878719-A1 | CRYSTAL POLYMORPH OF HYDROXYNOREPHEDRIN DERIVATIVE HYDROCHLORIDE | Kissei Pharmaceutical Co., Ltd. (JP) | 2008-01-16 | — | — | EP | claimed |
| US-20070088174-A1 | Synthesis of phenoxyacetic acid derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-19 | — | — | US | claimed |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| US-7763654-B2 | Crystal polymorph of hydroxynorephedrin derivative hydrochloride | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-7763654-B2 | Crystal polymorph of hydroxynorephedrin derivative hydrochloride | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-20100172988-A1 | SUSTAINED RELEASE PREPARATION AND METHOD FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-07-08 | — | — | US | disclosed |
| US-20100172988-A1 | SUSTAINED RELEASE PREPARATION AND METHOD FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-07-08 | — | — | US | disclosed |
| US-20090247781-A1 | SYNTHESIS OF PHENOXYACETIC ACID DERIVATIVES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20040242686-A1 | Crystals of hydroxynorephedrine derivative | KISSEI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| US-20040242686-A1 | Crystals of hydroxynorephedrine derivative | KISSEI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| WO-2004098586-A1 | USE OF PHENOXYACETIC ACID DERIVATIVES FOR TREATING HYPERACTIVE BLADDER | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | WO | disclosed |
| US-20040229947-A1 | Method of treating hyperactive bladder using phenoxyacetic acid derivatives | KISSEI PHARMACEUTICAL CO., LTD. | 2004-11-18 | — | — | US | disclosed |
| EP-1426355-A1 | CRYSTALS OF HYDROXYNOREPHEDRINE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-06-09 | — | — | EP | disclosed |
| EP-1426355-A1 | CRYSTALS OF HYDROXYNOREPHEDRINE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885LMNA 1686/4885SLC6A2 257/4885 |
| US-20070088174-A1 | Synthesis of phenoxyacetic acid derivatives | DDC, PAH, HPD | ADRB3 330/4885LMNA 2880/4885SLC6A2 49/4885 |
| US-20040229947-A1 | Method of treating hyperactive bladder using phenoxyacetic acid derivatives | BPHL, HTR5A, PNMT | ADRB3 123/4885LMNA 4385/4885SLC6A2 15/4885 |
| US-20090069421-A1 | CRYSTAL POLYMORPH OF HYDROXYNOREPHEDRIN DERIVATIVE HYDROCHLORIDE | HTR3A, HTR3C, HTR3B | ADRB3 536/4885LMNA 4007/4885SLC6A2 210/4885 |
| US-20090247781-A1 | SYNTHESIS OF PHENOXYACETIC ACID DERIVATIVES | DDC, PAH, HPD | ADRB3 315/4885LMNA 3124/4885SLC6A2 40/4885 |
| US-20100172988-A1 | SUSTAINED RELEASE PREPARATION AND METHOD FOR PRODUCTION THEREOF | APEH, BPHL, UROD | ADRB3 1337/4885LMNA 2967/4885SLC6A2 498/4885 |
| US-20040242686-A1 | Crystals of hydroxynorephedrine derivative | ADRA2C, ADRB2, ADRA2A | ADRB3 9/4885LMNA 2801/4885SLC6A2 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.